NCT05797246View on ClinicalTrials.gov

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 2, 2023

Primary Completion Date

November 24, 2025

Study Completion Date

November 2, 2026

Conditions
Respiratory Tract DiseasesNeoplasmsNeoplasms by Histologic TypeNeoplasms, Glandular and EpithelialNeoplasms, Squamous CellTumor Virus InfectionsInfectionsVirus DiseasesDNA Virus InfectionsPathologic ProcessesDisease AttributesRecurrencePapillomaRespiratory Tract InfectionsPapillomavirus Infections
Interventions
DRUG

Bevacizumab

10 mg/kg IV every three weeks for 3 cycles and then every 6 weeks for a total treatment course of 11 cycles for approximately 1 year total.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH